finanzen.net

Lotus Pharmaceuticals ;-)))

Seite 1 von 3
neuester Beitrag: 11.05.10 17:29
eröffnet am: 21.01.10 12:48 von: Kleine_prinz Anzahl Beiträge: 52
neuester Beitrag: 11.05.10 17:29 von: stockplayer Leser gesamt: 12431
davon Heute: 3
bewertet mit 2 Sternen

Seite:
| 2 | 3  

21.01.10 12:48
2

5783 Postings, 3884 Tage Kleine_prinzLotus Pharmaceuticals ;-)))

Der chinesische Pharmaproduzent verfüge bereits über vier am Markt etablierte Medikamentenmarken sowie über eine spannende Entwicklungspipeline. Lotus Pharmaceuticals vertreibe per Direktvertrieb mehr als 5.000 Arzneimittel und traditionelle chinesische Medizin sowie medizinisches Equipment. Des Weiteren betreibe die Gesellschaft 10 Apotheken im Stadtgebiet von Peking.

Zwischen den Jahren 2005 und 2008 seien die Umsätze um 300% von 18,4 Mio. USD auf 73,8 Mio. USD explodiert. Im gleichen Zeitraum habe sich der Nettogewinn von 1,83 Mio. auf 12,8 Mio. USD sogar versiebenfacht. Im zuletzt abgelaufenen 3. Quartal habe Lotus Pharmaceuticals eigenen Angaben zufolge bei Umsätzen von 14,5 Mio. USD einen Nettogewinn von 5,4 Mio. USD bzw. 0,11 USD pro Aktie erwirtschaftet. Auf das Gesamtjahr hochgerechnet seien das 0,45 USD je Aktie, wobei das 4. Quartal traditionell das stärkste des Jahres sei.

Bei einem Aktienkurs von 1,34 USD betrage das KGV gerade einmal 3, was vor dem Hintergrund der Wachstumsraten und der Zukunftsperspektiven nach Erachten der Experten völlig lächerlich sei.

Für die Experten von "Emerging Markets Investor" ist die Lotus Pharmaceuticals-Aktie ein klarer Verdreifachungskandidat für 2010. Das Papier werde sofort in das neue Musterdepot aufgenommen. (Ausgabe 01 vom 11.01.2010) (12.01.2010/ac/a/a)

Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.

 

http://www.finanzen.net/analyse/...e-Emerging_Markets_Investor_350193

 

21.01.10 13:15

5783 Postings, 3884 Tage Kleine_prinzLotus Pharmaceuticals wächst rasant

Capitalize on China’s Medical Reform with Lotus

Written on Friday, January 15th, 2010 by Rick Telfur

Lotus Pharmaceuticals, Inc. (OTC:LTUS) may not be as well known as Teva Pharmaceuticals (NASDAQ:TEVA) or Pfizer, Inc. (NYSE:PFE), but this undiscovered stock could pay big dividends thanks to China’s comprehensive medical reform…

Lotus Pharmaceuticals, Inc. (LTUS) is a rapidly growing China-based drug company that manufactures branded drugs and distributes them along with products produced by third-party manufacturers throughout the country.

The company was founded and opened its first pharmacy in Beijing in 1996 before purchasing a pharmaceutical manufacturer in 2002. Since then, the company began self-branding and self-patenting drugs and spreading its sales network across China.

In 2006, the company reached a key milestone when the local Beijing government approved insurance reimbursements for purchases from its retail pharmacies. And now, the company is planning its expansion throughout Inner Mongolia.

A Huge and Growing Chinese Market

Backed by Beijing’s $124 billion investment in health system reforms over the next several years, the entire healthcare industry in China will see strong growth in 2010, say analysts from Morgan Stanley’s research department.

China’s Gao Hua Securities agrees with this thesis and projects the country’s healthcare industry to grow at an average rate of 23% in 2010E, with 35-40% growth in rural areas. Meanwhile, the firm insisted that the strong, sustainable secular growth was not fully priced in to stocks.

Pharmaceutical stocks like Lotus will participate in this growth via the government’s drug reimbursements. Many experts believe that these reimbursements will become a key differentiator in the medium-term, with volume expansion outpacing margin pressures.

Lotus Repositions to Benefit in 2010

Lotus currently manufactures four branded drugs that are all listed on China’s national medical insurance catalog. While the company is transitioning to wholesale from retail, which could depress profits in the near-term, the drugs should provide stable revenues going forward.

Lotus’ strategy for 2010 includes (1) expanding their sales network to additional retail locations and hospitals, (2) increase quality drug offerings to more than 20 prescription drugs by the end of the year, (3) expand geographically into Inner Mongolia.

The Takeaway…

  • Lotus Pharmaceuticals is operating in one of the fastest growing healthcare markets in the world, and has seen its shares appreciate substantially over the year.
  • Lotus Pharmaceuticals has experienced lower financial results over the past few quarters amid pricing pressure and a switch from high-margin retail to low-margin wholesale.
  • Looking ahead, Lotus has ambitious expansion plans that could help it capitalize on growth in the Chinese market and deliver value to shareholders.

http://sumfolio.com/...alize-on-chinas-medical-reform-with-lotus-160/

Übersetzung in DE

http://de.babelfish.yahoo.com/...p=en_de&btnTrUrl=%C3%9Cbersetzen

 

 

21.01.10 13:29

5783 Postings, 3884 Tage Kleine_prinzHier als Info ;-)

Jahres werte die sich sehen lassen können ;-))))

http://www.google.co.uk/finance?q=OTC:LTUS&fstype=ii

Und hier ein Link für ständige News ;-)))

http://www.google.co.uk/finance?q=OTC%3ALTUS

 

21.01.10 13:32

5783 Postings, 3884 Tage Kleine_prinzPharmaceuticals & Healthcare ;-))

Lotus Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile--Aarkstore Enterprise
New report "Lotus Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile" available through Aarkstore.com 


Lotus Pharmaceuticals, Inc. (Lotus) operates and has ownership interests in Liang Fang Pharmaceutical, Ltd. (Liang) and En Zhe Jia Shi Pharmaceutical, Ltd. (En Zhe). Liang and En Zhe combinely engaged in the production, trade, sales and marketing of pharmaceuticals. In China, both companies possess some of the most advanced pharmaceutical-production equipment. The company owns and operates 10 drug stores in Beijing, China, engaged in the sale of western and traditional Chinese medications, lease medical treatment facilities. The company has the major operations in China. The company is headquartered at Beijing, China

Lotus Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company’s major recent financial deals.

Scope

- Provides key company information for business intelligence needs
- Gives information on the company’s major recent financial deals including Mergers and Acquisitions, asset transactions, PE/VC deals, equity offerings, debt offerings and partnerships.
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.

For more information please visit :
http://www.aarkstore.com/reports/...-and-Alliances-Profile-20346.html 

 

http://www.prminds.com/pressrelease.php?id=24767  

21.01.10 14:44

5783 Postings, 3884 Tage Kleine_prinzLotus Pharmaceuticals Announces Key Changes

Lotus Pharmaceuticals Announces Key Changes 

BEIJING, Jan. 15 /PRNewswire-Asia-FirstCall/ --

Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that its newly engaged auditor is Friedman LLP and legal counsel McLaughlin & Stern LLP.

The Company was notified that the audit practice of Bagell, Josephs, Levine & Company, LLP, the Company's independent registered public accounting firm ("BJL"), joined with Friedman LLP ("Friedman") effective as of January 1, 2010. On January 12, 2010, BJL resigned as the independent registered public accounting firm of the Company and, with the approval of the Audit Committee of the Company's Board of Directors, Friedman was engaged as the Company's current independent registered public accounting firm.

BJL was engaged as the Company's independent accountants on April 24, 2009. From April 24, 2009 through January 12, 2010, there were no disagreements between the Company and BJL on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to its satisfaction, would have caused BJL to make reference to the subject matter of such disagreements in connection with its report,

The Company has also engaged McLauglin & Stern, LLP. as its securities legal counsel.

CEO, Zhongyi Liu, said, "We are looking forward to working with our new auditor and legal counsel to add values for our shareholders."

About Friedman LLP

Friedman LLP, Accountants and Advisors, is headquartered in New York City with offices in New Jersey and Long Island. As of January 1, 2010, Friedman LLP has over 325 professionals and personnel, providing accounting, tax and consulting services to public and privately held companies. For further information, please visit http://www.friedmanllp.com .

About McLaughlin & Stern, LLP.

McLaughlin & Stern, LLP, established in 1898, is one of New York's oldest law firms. The firm provides a diverse range of sophisticated legal services to businesses and individuals, offering legal expertise in mergers and acquisitions, corporate finance, litigation, real estate, intellectual property, health care, family law, tax, environmental law, maritime law, art law, trusts and estates and other private client matters. It has 70 lawyers in New York City, Milbrook, New York and West Palm Beach, Florida. For more information, please visit http://www.mclaughlinstern.com .

About Lotus Pharmaceuticals, Inc. ( http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

For more information, please contact: Lotus Pharmaceuticals, Inc. Yan ZENG, CFO Tel: +86-10-6389-9868 Email: zy@lotuspharma.com

 

SOURCE Lotus Pharmaceuticals, Inc.

RELATED LINKS
http://www.lotuspharma.com
http://www.friedmanllp.com
http://www.mclaughlinstern.com

 

 

 

http://www.lotuspharma.com/Press%20Release2010-01-15.html

 

21.01.10 15:05

5783 Postings, 3884 Tage Kleine_prinzEnd of 2010 with an estimated 25% in net margin

Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores

BEIJING, Nov. 30 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company") a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), today reported that its Over-the-Counter Drug division ("OTC Division") successfully entered into supply contracts with more than five hundred drug stores in Beijing as of today. The Company already has direct purchase contracts in place with around 300 manufacturers nationwide to distribute more than 800 types of medicines. All contracts have a term from one to two years and are renewable upon mutual agreement.

"I'm pleased with the experienced sales force of our OTC Division," said Dr. Zhong Yi Liu, Chairman and Chief Executive Officer of the Company. "Since the establishment of the OTC Division at the end of the last year, we have demonstrated substantial success in entering this new market segment in Beijing. Our market research shows that the current sales revenue for 4,500 drug stores in Beijing is estimated to be in the aggregate RMB 5 billion per year. Looking forward, we believe that our revenues generated from direct sales to drug stores could contribute around RMB 60 million to net revenues by the end of 2010 with an estimated 25% in net margin."

The Company believes it will be able to enter into purchase agreements with a total of approximately 900 manufacturers throughout the PRC by the end of 2012. The Company also believes it will be able to enter into supply contracts with approximately 2,000 drug stores by 2012 and gradually become their main supplier of majority drugs. Since the Company is currently planning to build a 10,000 square meter modern storage in the new general office building in Chaoyang District of Beijing, and to put it into use by the third quarter of 2010, the Company believes it could realize annual sales of around RMB 200 million by 2012.

About Lotus Pharmaceuticals, Inc. (http://www.lotuspharma.com )

Lotus Pharmaceuticals, Inc. is a growing developer and producer of prescription drugs and a licensed national seller of pharmaceutical items in the People's Republic of China. Lotus operates Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. More than 8,000 products are sold by Liang Fang directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

For more information, please contact: Lotus Pharmaceuticals, Inc. Yan ZENG, CFO Phone: +86-10-6389-9868 Email: zy@lotuspharma.com

 

SOURCE Lotus Pharmaceuticals, Inc.

RELATED LINKS
http://www.lotuspharma.com

http://www.prnewswire.com/news-releases/...-drug-stores-78125372.html

Das Ganze in DE ;-))

http://de.babelfish.yahoo.com/...p=en_de&btnTrUrl=%C3%9Cbersetzen

 

21.01.10 20:27

5783 Postings, 3884 Tage Kleine_prinzLotus Pharmaceuticals kaufen :-))

Analysen Empfehlungen 21.12.09, 12:14 HOT STOCKS INVESTOR Lotus Pharmaceuticals kaufen

Endingen (aktiencheck.de AG) - Die Experten von "Hot Stocks Investor" raten die Lotus Pharmaceuticals-Aktie (ISIN US5457151042/ WKN A0MNCW) zu kaufen.

Das Unternehmen verfüge über eine spannende Entwicklungspipeline. Laevo-Bambutero, ein in Testreihen hoch effektives Mittel gegen Asthma, sei einer der Hoffnungsträger des Unternehmens. Das Präparat sei im vergangenen Jahr einlizensiert worden und solle 2012 auf den Markt kommen. Der Markt für Asthma-Präparate habe in China einen Umfang von 3 Mrd. USD. Schon heute sei China der fünftgrößte Arzneimittelmarkt der Welt. Die Umsätze in diesem Bereich würden sich von 11,7 Mrd. USD in 2005 auf 24 Mrd. USD in 2010 mehr als verdoppeln. Ein schier unbegrenztes Wachstumspotenzial biete sich durch den wachsenden Lebensstandard sowie die demografische Entwicklung.

Lotus Pharmaceuticals könnte mit einer über Jahre hinweg bestens eingeführten und etablierten Produktpipeline und einer sehr spannenden Forschungssparte in diesem Markt kaum besser positioniert sein. Und doch sei die Aktie aktuell noch sehr günstig zu haben. Das bestätige ein Blick auf die Ergebnisse. Die Umsätze des Unternehmens seien zwischen 2005 und 2008 von 18,4 Mio. auf 73,8 Mio. USD gestiegen, das seien 300%. Im gleichen Zeitraum habe der Nettogewinn von 1,83 auf 12,8 Mio. USD sogar versiebenfacht werden können.

Die Gesellschaft habe zuletzt für das 3. Quartal 2009 einen Umsatz von 14,5 Mio. USD erwirtschaftet. Es sei ein Nettogewinn von 5,4 Mio. USD bzw. 0,11 USD je Aktie ausgewiesen worden. Nach neun Monaten könne Lotus Pharmaceuticals einen Umsatz von 40 Mio. USD und einen Net Profit von 13,7 Mio. USD bzw. 0,32 USD je Anteilsschein vorweisen. Das 4. Quartal sei traditionell das stärkste. Umsatz und Ergebnis dürften deshalb bis zum Ende des Jahres noch einmal deutlich zulegen. Die Aktie sei gemäß den Experten mit einem 2009er-KGV von 2 bis 3 lächerlich niedrig bewertet.

Laut den Experten von "Hot Stocks Investor" ist die Lotus Pharmaceuticals-Aktie ein klarer Kauf. (Ausgabe 24 vom 21.12.2009) (21.12.2009/ac/a/a)

Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.

http://analysen.onvista.de/empfehlungen/artikel/...?ID_NEWS=129629462

 

22.01.10 14:31

5783 Postings, 3884 Tage Kleine_prinzthe anti-asthma by 2012

Lotus purchased the patent and exclusive production rights in April 2008 to Laevo-Bambutero, a highly effective asthma drug for which the Company hopes to get manufacturing and distribution approval from China¡¯s State Food and Drug Administration (SFDA) by 2012. One of the Company¡¯s affiliates, En Ze Jia, entered into a Technology Transfer Agreement with Dong Guan Kai Fa Biologicals Medicine LTD (¡°Dong Guan¡±) through which Dong Guan agreed to transfer the technology material, new medicine research and rights to the Chinese patent of the anti-asthma new medicine Laevo-Bambutero to En Ze Jia on an exclusive basis in exchange for a transfer technology fee of approximately $7 million (RMB 48 million).

Lotus has a number of drugs waiting approval from the SFDA

Drug NameTarget Area
Sodium aescinateCentral nervous system
Gatifloxacin lactateAnti-infectives
Calcium dibutyryl adenosine-monophosphateCardiovascular
GliclazideDiabetes
Salbutamol sulfateRespiratory
Rabeprazole sodiumGastrointestina
Compound allantoinGastrointestinal
NimesulideInflammatory
LovastatinCardiovascular
Compound metoprolo felodipineCardiovascular
CandesartanCardiovascular
Hawthorn flavonoidsCardiovascular
Compound balloonflower granulesRespiratory
Aster monomerInflammatory
 

22.01.10 14:47

5783 Postings, 3884 Tage Kleine_prinzChanges in Registrant's Certifying Accountant

Form 8-K for LOTUS PHARMACEUTICALS, INC.


15-Jan-2010

Changes in Registrant's Certifying Accountant, Other Events, Financia


Item 4.01 Changes in Registrant's Certifying Accountant

Lotus Pharmaceuticals Inc. (the "Company") was notified that Bagell, Josephs, Levine & Company, LLP, the Company's former independent registered public accounting firm ("BJL"), merged their practice into Friedman LLP ("Friedman") effective as of January 1, 2010. As a result, on January 12, 2010 BJL resigned as the Company's independent registered public accounting firm and, on January 12, 2010, Friedman was engaged as the Company's new independent registered public accounting firm of the Company. The change of the independent accounting firm was approved by the Audit Committee of the Company's Board of Directors.

During the past two fiscal years ended December 31, 2009 and December 31, 2008, or any subsequent period prior to the engagement of Friedman on January 12, 2009, the Company did not consult with Friedman regarding any matter described in Item 304(a)(2) of Regulation S-K, including any issues related to Company's financial statements or the type of audit opinion that might be rendered for the Company.

BJL was engaged on April 24, 2009 and between the date thereof through the date of the resignation on January 12, 2010, the BJL's reports on the Company's financial statements for the periods did not contain any adverse opinions or disclaimer opinions, nor were the reports qualified or modified as to uncertainty, audit scope or accounting principles. Furthermore, BJL's reports did not include any disclosure of uncertainty regarding the Company's ability to continue as a going concern.

From April 24, 2009 through the date of resignation on January 12, 2010, including the fiscal year ended December 31, 2009 and the subsequent interim period, there were no (i) disagreements between the Company and BJL on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to its satisfaction, would have caused BJL to make reference to the subject matter of such disagreements in connection with its report, or (ii) "reportable events," as described in Item 304(a)(1)(v) of Regulation S-K.

The Company furnished BJL with a copy of this Current Report on Form 8-K and requested BJL furnish a letter addressed to the Securities and Exchange Commission stating whether or not BJL agrees with the statements in this 8-K. A copy of this letter dated January 13, 2010 is attached hereto as Exhibit 16.1.

 



Item 8.01 Other Events

On January 15, 2010 Lotus Pharmaceuticals, Inc. issued a press release announcing the engagement of Friedman and the engagement of McLaughlin & Stern, LLP based in New York, NY as its legal counsel for securities law related matters. A copy of such press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

 



Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

16.1 Letter dated January 13, 2010 from Bagell, Josephs, Levine & Company, LLP.

99.1 Press release issued by Lotus Pharmaceuticals, Inc. on January 15, 2010.

http://biz.yahoo.com/e/100115/ltus.ob8-k.html

 

23.01.10 18:17

5783 Postings, 3884 Tage Kleine_prinzKräftige Gewinnmitnahmen

ist doch klar bei so eine Steilkurve ;-)

Financial Strength
Revenue (TTM)$65,973,060
Earnings (TTM)$20,146,411
Quick Ratio0.3:1
Current Ratio0.5:1
Total Debt/Equity0.09:1
Profitability
Gross Margin55.1%
EBITDA Margin37.3%
Profit Margin30.8%
 

25.01.10 19:14

5783 Postings, 3884 Tage Kleine_prinzErste Kursziel 4 $ "Emerging Markets Investor" ;-)

Bei einem Aktienkurs von 1,34 USD betrage das KGV gerade einmal 3, was vor dem Hintergrund der Wachstumsraten und der Zukunftsperspektiven nach Erachten der Experten völlig lächerlich sei.

Für die Experten von "Emerging Markets Investor" ist die Lotus Pharmaceuticals-Aktie ein klarer Verdreifachungskandidat für 2010. Das Papier werde sofort in das neue Musterdepot aufgenommen. (Ausgabe 01 vom 11.01.2010) (12.01.2010/ac/a/a)

 http://www.finanzen.net/analyse/...e-Emerging_Markets_Investor_350193

 http://www.finanzen.net/analyse/..._kaufen-Hot_Stocks_Investor_349306

 

26.01.10 17:15

5783 Postings, 3884 Tage Kleine_prinz*g* Heftig da scheint jemand ein..

Wenig Nervös zu sein *g*

 

Tja schön auf den Richtigen Moment abwarten bist es wieder hoch geht ;-)

Manchmal kann man von Panik gut Profiteren ;-)

Wenn eine Aktie Sinnlos runter geht ;-)

 

 

26.01.10 18:27

5783 Postings, 3884 Tage Kleine_prinzund nicht vergessen ;-)

Meldung von Friday, January 15th, 2010 ;-)))

http://sumfolio.com/...alize-on-chinas-medical-reform-with-lotus-160/

Mal durch ein übersetzer programm gejagt.. :-))

 Häufen Sie auf Chinas Medizinischer Reform mit der Lotusblume Kapital an
Geschrieben am Freitag, dem 15. Januar 2010 von Rick Telfur

Lotus Pharmaceuticals, Inc (OTC:LTUS) darf nicht ebenso als Arzneimittel von Teva (NASDAQ:TEVA) oder Pfizer, Inc (NYSE:PFE) bekannt sein, aber dieses unentdeckte Lager konnte große Dividende dank Chinas umfassender medizinischer Reform zahlen …

Lotus Pharmaceuticals, Inc (LTUS) ist eine schnell wachsende chinesisch-basierte Drogenfirma, die gebrandmarkte Rauschgifte verfertigt und sie zusammen mit Produkten verteilt, die von Drittherstellern im ganzen Land erzeugt sind.

Die Gesellschaft wurde gegründet und öffnete seine erste Apotheke in Beijing 1996 vor dem Kaufen eines pharmazeutischen Herstellers 2002. Seitdem begann die Gesellschaft, Rauschgifte selbstzubrandmarken und selbstzupatentieren und sein Vertriebsnetz über China auszubreiten.

2006 erreichte die Gesellschaft einen Schlüsselmeilenstein, als die lokale Beijinger Regierung Versicherungserstattungen für Käufe von seinen Einzelapotheken genehmigte. Und jetzt plant die Gesellschaft seine Vergrößerung überall in der Inneren Mongolei.

Ein Riesiger und Wachsender chinesischer Markt

Unterstützt durch Beijings Investition von $ 124 Milliarden in Gesundheitssystemreformen im Laufe der nächsten mehreren Jahre wird die komplette Gesundheitsfürsorge-Industrie in China starkes Wachstum 2010 sehen, Analytiker von der Forschungsabteilung von Morgan Stanley sagen.

Chinas Gao Hua Securities stimmt mit dieser These überein und plant die Gesundheitsfürsorge-Industrie des Landes, um an einem Durchschnittssatz von 23 % in 2010E mit 35-40-%-Wachstum in ländlichen Gebieten zu wachsen. Inzwischen bestand das Unternehmen darauf, dass das starke, nachhaltige weltliche Wachstum in zu Lagern nicht völlig bewertet wurde.

Pharmazeutische Lager wie Lotusblume werden an diesem Wachstum über die Rauschgift-Erstattungen der Regierung teilnehmen. Viele Experten glauben, dass diese Erstattungen ein Schlüssel differentiator im mittelfristigen mit der Volumen-Vergrößerung werden werden, die Hinterlegungssumme-Druck aussticht.

Lotusblume-Wiederpositionen, 2010 Vorteil zu haben

Lotusblume verfertigt zurzeit vier gebrandmarkte Rauschgifte, die alle auf Chinas nationalem Krankenversicherungskatalog verzeichnet werden. Während die Gesellschaft zum Großhandel vom Einzelhandel wechselt, der Gewinne im kurzfristigen niederdrücken konnte, sollten die Rauschgifte stabilen Einnahmen das Vorankommen zur Verfügung stellen.

Die Strategie der Lotusblume für 2010 schließt (1) Erweiterung ihres Vertriebsnetzes zu zusätzlichen Einzelpositionen und Krankenhäusern, (2) ein Zunahme-Qualitätsrauschgift-Angebote zu mehr als 20 verschreibungspflichtigen Medikamenten am Ende des Jahres, (3) breiten sich geografisch in die Innere Mongolei aus.

Lotusblume-Arzneimittel funktionieren auf einem der schnellsten wachsenden Gesundheitsfürsorge-Märkte in der Welt, und haben seine Aktien gesehen wesentlich im Laufe des Jahres schätzen.


· Lotusblume-Arzneimittel haben niedrigere Finanzergebnisse über die vorigen wenigen Quartale mitten in der Preiskalkulation des Drucks und eines Schalters vom Einzelhandel der hohen Hinterlegungssumme bis Großhandel der niedrigen Hinterlegungssumme erfahren.


· Vorn schauend, hat Lotusblume ehrgeizige Vergrößerungspläne, die ihr helfen konnten, auf dem Wachstum auf dem chinesischen Markt Kapital anzuhäufen und Wert an Aktionäre zu liefern.

 

26.01.10 20:01

5783 Postings, 3884 Tage Kleine_prinzDon't Cry Over Spilt Milk ;-)))

 

Dont Cry Over Spilt Milk

SmallCapInvestor.com Staff , On Monday January 25, 2010, 12:00 am EST

I hope everyone had a good weekend after what was a rather bloody week in the financial markets. The price action was ugly, to say the least, with selling that only accelerated into the close on Friday. I was watching the Russell 2000 small-cap index, which was only down modestly mid-day Friday, but then dropped moving into the close to finish the day down 1.8%. 

For the week, the Russell fell 3.3%. Not too bad actually, considering the Dow dropped 4.1%, the Standard and Poor 500 was down 3.9%, and the Nasdaq declined 4.8%. Like I said on Thursday, I find the Russell's resiliency in the sell-off to be encouraging for small-cap investing in 2010, since we would usually expect the index to fall more that the large-cap indexes.

I expect the Russell will hold around 620, or risk falling closer to 600. It closed last week at 617, right around my first support line. In the pre-market today, it looks like the major indices will all open higher on news that Fed Chief Ben Bernanke is closer to securing a second term.

But let's not waste our time crying over last week's spilled milk. I'd rather give you an update on a stock that I recommended back on September 2, 2009 to subscribers of SmallCapInvestor PRO . Since I recommended it the stock is up 110% and I'm confident there are more gains to come.

The company is Lotus Pharmaceuticals (OTC BB: LTUS), and it was featured in my Special Report: The 10 Most Profitable Small Cap Stocks for 2010 when it was a $0.79 stock.

Dean B. wrote in asking for an update on the stock. Subscribers to SmallCapInvestor PRO  know that I give weekly updates on portfolio stocks, but since Lotus wasn't added to the portfolio (I can't include every good stock I find, since I need to keep the portfolio to a manageable size) I haven't been tracking Lotus as closely.

"Ian, I purchased LTUS for $1.00 and have enjoyed its appreciation thus far to $1.80.  There is very little information about this stock and was wondering if you could give the Small Cap Investor [subscribers] an update on this particular company. Should I continue to hold this stock, or take some profits?  Thanks for your stock picking guidance."

Lotus Pharmaceuticals fell pretty hard on Friday - it was down 12% on the day to close at $1.66. Still, subscribers who purchased shares of this speculative drug stock when my special report came out are sitting on gains of 110%, and Dean is up 66%. My initial price target for Lotus was $2.10, and it came pretty close before the recent sell-off. It closed at $1.95 on Wednesday, January 20.

Lotus Pharmaceuticals produces prescription drugs and is a licensed national seller of pharmaceutical items in the People's Republic of China. The company's drug development pipeline is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Recently, the company received a patent pending notice from China's Intellectual Property Office for Gliclazide-Controlled Release Tablets, a drug treatment that is aimed at type-2 diabetes.

Lotus has made the first installment payment to acquire the patent as part of its continued effort to build its intangible asset base. If and when this drug hits the production phase, shares of Lotus stock could soar.  

Development stage pharmaceuticals are highly speculative, since these companies often have no revenues, and minimal capital. Shares of stock will swing wildly in both directions. Fortunately, shares of Lotus offer investors some fundamental underpinnings since ongoing operations are already profitable – otherwise I wouldn't have recommended it.

In the third quarter of 2009 Lotus reported $5.4 million in net income, or $0.11 per diluted share, on $14.5 million in net revenue.  This resulted in a 37% profit margin, an increase over the comparable quarter in 2008 when the profit margin was 19%.

That margin improvement was the result of strong performance in the company's wholesale business (which accounts for 80% of net revenues) and solid cost management. Clearly, management's efforts to focus on operational efficiency showed in the quarterly results. Despite a decrease in net revenue of 13% (net revenue in the third quarter of 2008 was $16.7 million), net income increased 69% and earnings per diluted share increased 57%.

According to the company's third quarterly filing, Lotus faces two headwinds: a 42% decrease in average unit selling price due to deflation in raw material costs, and delays in completing its new manufacturing facility in Inner Mongolia. Those delays are mostly the result of trimming back on its investments to complete the facility in order to shore up current operations.

I think Lotus's quarterly results show that it has been able to effectively mitigate these pressures since a 39% increase in wholesale sales volume and the operational efficiency gains resulted in strong financial performance.

Since those quarterly results were released on November 16 2009, the company has secured 500 contracts (in addition to the 300 it already had) with drug stores in Beijing to supply over-the-counter (OTC) medicines, brought in a new leader to head the OTC Divisions expansion, and clarified language regarding its corporate structure that had previously raised investors' eyebrows. The company, like many in China, is a holding company and is structured as such to allow for foreign investment. It is also continuing to invest in its product pipeline.

It's likely that sales in 2009 will be lower than in 2008, but the improved efficiency and profitability indicates to me that this is a company that is getting its internal house in order and getting ready for future growth.  I find this very encouraging as an investor.
I'd recommend holding onto Lotus Pharmaceutical for now. The growth prospects are just too good and despite some headwinds, this stock has been a strong performer. Plus, shares are dirt cheap on a valuation basis. Trailing-12 month earnings per share are $0.41, yielding a PE multiple of only 4. Just sit tight while this stock fluctuates and in another six months you'll be very glad you did. It's not unreasonable to think that shares could double in the next year.   

This has been a great stock for subscribers to SmallCapInvestor PRO who read my Special Report. In my Special Report: The 10 Most Profitable Small Cap Stocks for 2010, there are 9 other highly profitable small-cap stocks worth your attention.  In fact, five of them made it into my model portfolio and you'll receive weekly updates on them as a subscriber.

You can find out more when you sign up for SmallCapInvestor PRO, just click here to get started.

Keep sending me your questions, my address is editorial@smallcapinvestor.com. I'll give you my thoughts in a future issue.

*** I still see tremendous long-term potential investing in China. Sure, there will be ups and downs like last week, but over time, investors will make a lot of money on Chinese stocks.

For more on my Chinese investment strategies, you can watch the replay of my investing seminar conference from last week - China Inc.: Understanding China for Outstanding Profits. You can watch the video by clicking here now.

http://finance.yahoo.com/news/...investor-455853401.html?x=0&.v=2

 

26.01.10 20:11

5783 Postings, 3884 Tage Kleine_prinzSchreit nicht bei verschüttete Milch :-))

http://finance.yahoo.com/news/...investor-455853401.html?x=0&.v=2

Das Ganze in DE oder sowas ähnliches ;-)))

Denke man kann es verstehen.. Übersetzung durch Babel Fish

--------------------------------------------------

Schreit nicht bei verschüttete Milch

SmallCapInvestor.com-Personal am Montag, dem 25. Januar 2010 12:00 morgens EST

Ich hoffe, dass jeder ein gutes Wochenende hatte nach, was eine ziemlich blutige Woche in den Geldmärkten war. Die Preistätigkeit war gelinde gesagt mit dem Verkauf das hässlich, das nur in den Abschluss am Freitag beschleunigt wurde. Ich passte den Russell Kleinkappe Index 2000, der nur hinunter bescheiden Mittag Freitag war, aber andererseits fallengelassenes in nah an Ende sich bewegen der Tag hinunter 1.8% auf. 

Für die Woche fiel der Russell 3.3%. Nicht auch waren Schlechtes wirklich, in der Erwägung das Dow 4.1% fallenließen, das Standard und die Armen 500 hinunter 3.9%, und das Nasdaq sank 4.8%. Wie ich am Donnerstag sagte, finde ich die des Russells Elastizität im Sell-off, um für die Kleinkappe aufmunternd zu sein, die 2010 investiert, da wir normalerweise den Index erwarten würden, um mehr zu fallen dass die Großkappe Indizes.

Ich erwarte, dass der Russell herum 620 hält oder riskiere, näeher an 600 zu fallen. Er schloß letzte Woche bei 617, recht um meine erste Deckungslinie. In der Vorbörse heute, sieht er wie die Hauptindizes wird alle aus, die höher auf Nachrichten geöffnet sind, dass Fed HauptBen Bernanke näeher an dem Sichern eines zweiten Ausdruckes ist.

Aber lassen Sie uns unsere Zeit nicht vergeuden, die über von letzter Woche verschütteter Milch schreit. Ich würde Ihnen ein Update auf einem Vorrat eher geben, den ich zurück am 2. September 2009 den Teilnehmern von SmallCapInvestor PRO empfahl. Da ich es empfahl, das der Vorrat herauf 110% ist und ich bin dort bin mehr Gewinne überzeugt, zum zu kommen.

Die Firma ist Lotos-pharmazeutische Produkte (OTC BB: LTUS) und er wurden in meinem Sonderbericht gekennzeichnet: Die 10 rentabelsten Bagatellaktien für 2010, als es ein Vorrat $0.79 war.

Dekan B. schrieb beim Bitten um ein Update auf den Vorrat. Teilnehmer zu PRO SmallCapInvestor wissen, dass ich wöchentliche Updates auf Mappenaktien gebe, aber, da Lotos nicht der Mappe hinzugefügt wurde (ich kann jeden guten Vorrat nicht mit einschließen, den ich finde, da ich die Mappe zu einer handlichen Größe halten muss,) ich nicht Lotos als nah aufgespürt habe.

„Ian, kaufte ich LTUS für $1.00 und habe seine Anerkennung bis jetzt bis $1.80 genossen.  Es gibt sehr wenig Informationen über diesen Vorrat und wunderte sich, wenn Sie dem kleine Kappen-Investor [Teilnehmern] ein Update auf dieser bestimmten Firma geben konnten. Sollte ich fortfahren, diesen Vorrat zu halten, oder nehmen Sie einige Profite?  Dank für Ihre auf lagersammelnanleitung.“

Lotos-pharmazeutische Produkte fielen recht stark am Freitag - sie war hinunter 12% am Tag, zum bei $1.66 zu schließen. Noch sitzen Teilnehmer, die Anteile dieses spekulativen Drogevorrates kauften, als mein Sonderbericht herauskam, auf Gewinnen von 110% und Dekan ist herauf 66%. Mein Anfangspreisziel für Lotos war $2.10, und es kam recht nah vor dem neuen Sell-off. Es schloß bei $1.95 am Mittwoch, dem 20. Januar.

Lotos-pharmazeutische Produkte produziert verschreibungspflichtige Medikamente und ist ein genehmigter nationaler Verkäufer der pharmazeutischen Einzelteile in der Volksrepublik China. Die Droge-Entwicklungsrohrleitung der Firma wird auf die Behandlung der cerebro-kardiovaskulären Krankheit, des Asthmas und des Diabetes gerichtet. Vor kurzem empfing die Firma eine Patentnachricht Chinas vom geistiges Eigentum-Büro für Gliclazide-Kontrollierte Freigabe-Tabletten, eine Drogebehandlung, die angestrebter Type-2diabetes ist.

Lotos hat die erste Ratenzahlungszahlung geleistet, um das Patent als Teil seiner anhaltenden Bemühung zu erwerben, seine Unterseite des immateriellen Guts zu errichten. Wenn und wenn diese Droge die Produktionsphase schlägt, konnten Anteile des Lotosvorrates ansteigen.  

Entwicklungsstadiumspharmazeutische produkte sind in hohem Grade spekulatives, da diese Firmen häufig keine Einkommen haben, und minimales Kapital. Kapitalanteile schwingen wild in beiden Richtungen. Glücklicherweise bieten Anteile von Lotos Investoren einige grundlegende Untermauerung an, da laufende Betriebe bereits rentabel sind - andernfalls würde ich nicht es empfohlen haben.

Im dritten Trimester von Lotos 2009 berichtete $5.4 Million im Reineinkommen oder über $0.11 pro verdünnten Anteil, auf $14.5 Million in der Reineinnahme.  Dieses ergab eine 37% Gewinnspanne, eine Zunahme über dem vergleichbaren Viertel 2008, als die Gewinnspanne 19% war.

Diese Seitenrandverbesserung war das Resultat der starken Leistung im Großhandel der Firma (der 80% von Reineinnahmen beträgt) und festes Kostenmanagement. Offenbar zeigten Bemühungen des Managements, sich auf Betriebs-Leistungsfähigkeit zu konzentrieren in den vierteljährlichen Resultaten. Trotz einer Abnahme an der Reineinnahme von 13% (Reineinnahme im dritten Trimester von 2008 war $16.7 Million), erhöhte Reineinkommen 69% und Einkommen pro verdünnten Anteil erhöhte 57%.

Entsprechend der dritten vierteljährlichen Archivierung der Firma stellt Lotos zwei widrige Winde gegenüber: eine 42% Abnahme am Verkaufspreis der durchschnittlichen Maßeinheit wegen der Deflation im Rohstoff kostet und verzögert, wenn sie seine neue Produktionsanlage in Inner Mongolia abschließt. Jene Verzögerungen sind meistens das Resultat zurück trimmen, auf seine Investitionen, zum der Anlage abzuschließen, um gegenwärtige Betriebe abzustützen.

Ich denke, dass vierteljährliche Resultate des Lotos zeigen, dass es in der Lage gewesen ist, diesen Druck seit einer 39% Zunahme des Großhandelsumsatzes effektiv abzuschwächen und die Betriebs-Leistungsfähigkeits-Gewinne starke Finanzleistung ergaben.

Seit jene vierteljährlichen Resultate am 16. November 2009 freigegeben wurden, hat die Firma 500 Verträge (zusätzlich zu den 300, die sie bereits hatte), mit Drogespeichern in Peking gesichert, um im Freiverkehr gehandelte Medizin (OTC) zu liefern, in einen neuen Führer holte, um die OTC Abteilungsexpansion voranzugehen und erklärte Sprache betreffend seine Unternehmensstruktur, die vorher Augenbrauen der Investoren angehoben hatte. Die Firma, wie viele in China, ist eine Dachgesellschaft und wird als solcher strukturiert, zum Auslandsinvestition zuzulassen. Sie fährt auch fort, in seiner Produktrohrleitung zu investieren.

Es ist wahrscheinlich, dass Verkäufe in 2009 niedriger als 2008 sind, aber die verbesserte Leistungsfähigkeit und die Rentabilität teilt mir mit, dass dieses eine Firma ist, die sein internes Haus im Auftrag wird und zum zukünftigen Wachstum fertig erhält.  Ich finde dieses sehr aufmunternde als Investor.
Ich würde mich empfehlen, auf Lotos pharmazeutisch fürs Erste zu halten. Die Wachstumaussichten sind gerade zu gut und trotz einiger widriger Winde, ist dieser Vorrat ein starkes Ausführendes gewesen. Plus, Anteile sind Schmutz - billig auf einer Schätzungbasis. Einnahmen pro Aktie des Monats Trailing-12 Verdienstpotenzial sind $0.41 und erbringen eine PET-Mehrfachverbindungsstelle von nur 4. Sitzen Sie einfach festes, während dieser Vorrat schwankt und in anderen sechs Monaten Sie Sie taten sehr froh sind. Es ist nicht unvernünftig, zu denken, dass könnte im nächsten Jahr sich verdoppeln teilt.   

Dieses ist ein großer Vorrat für Teilnehmer zu PRO SmallCapInvestor gewesen, wer meinen Sonderbericht las. In meinem Sonderbericht: Die 10 rentabelsten Bagatellaktien für 2010, dort sind 9 andere in hohem Grade rentable Kleinkappe Aktien wert Ihre Aufmerksamkeit.  Tatsächlich bildeten fünf von ihnen sie in meine vorbildliche Mappe und Sie empfangen wöchentliche Updates auf ihnen als Teilnehmer.

Sie können mehr herausfinden, wenn Sie sich für PRO SmallCapInvestor anmelden, klicken gerade hier, um begonnen zu erhalten.

Halten Sie, mir Ihre Fragen zu schicken, meine Adresse ist editorial@smallcapinvestor.com. Ich gebe Ihnen meine Gedanken in einer zukünftigen Ausgabe.

*** I sehen noch ungeheures langfristiges Potenzial, in China zu investieren. Sure gibt es Höhen und Tiefen wie letzte Woche, aber im Laufe der Zeit, verdienen Investoren viel Geld auf chinesischen Aktien.

 

 

http://de.babelfish.yahoo.com/...p=en_de&btnTrUrl=%C3%9Cbersetzen

 

26.01.10 20:38

5783 Postings, 3884 Tage Kleine_prinzWow 500 Verträge zusätzlich ;-)))

am 16. November 2009 freigegeben wurden, hat die Firma 500 Verträge (zusätzlich zu den 300, die sie bereits hatte),

------------------------------------------------- 

Since those quarterly results were released on November 16 2009, the company has secured 500 contracts (in addition to the 300 it already had) with drug stores in Beijing to supply over-the-counter (OTC) medicines, brought in a new leader to head the OTC Divisions expansion, and clarified language regarding its corporate structure that had previously raised investors' eyebrows. The company, like many in China, is a holding company and is structured as such to allow for foreign investment. It is also continuing to invest in its product pipeline.

------------------------------------------------- 

Na dann wird es hier sehr Bald, es deutlich zu spüren sein ;-))))

 

27.01.10 18:31

5783 Postings, 3884 Tage Kleine_prinzLotus Pharmaceuticals New "Blockbuster"? ;-))

Es schaut absolut sehr danach aus ;-)


Ein News Report als Info....;-))

 

"ACHTUNG KEINE KAUFEMPFEHLUNG"


---------------------------------------------


Published Date : Monday January 25, 2010


Dont Cry Over Spilt Milk


SmallCapInvestor.com Staff , On Monday January 25, 2010, 12:00 am EST
 The 10 Most Profitable Small Cap Stocks for 2010....
Since those quarterly results were released on November 16 2009, the company has secured 500 contracts (in addition to the 300 it already had) with drug stores in Beijing to supply over-the-counter (OTC) medicines, brought in a new leader to head the OTC Divisions expansion, and clarified language regarding its corporate structure that had previously raised investors' eyebrows. The company, like many in China, is a holding company and is structured as such to allow for foreign investment. It is also continuing to invest in its product pipeline.

http://finance.yahoo.com/news/...-smallcapinvestor-455853401.html?x=0


---------------------------------------------

Published Date : January 15th, 2010


Capitalize on China’s Medical Reform with Lotus
Written on Friday, January 15th, 2010 by Rick Telfur


Lotus’ strategy for 2010 includes (1) expanding their sales network to additional retail locations and hospitals, (2) increase quality drug offerings to more than 20 prescription drugs by the end of the year, (3) expand geographically into Inner Mongolia.


http://sumfolio.com/...alize-on-chinas-medical-reform-with-lotus-160/
 

---------------------------------------------

 Published Date : 12.01.2010 Der Aktionaer

 Emerging Markets Investor: Verdreifachungskandidat Lotus Pharma

 

http://www.deraktionaer.de/xist4c/web/...upe_id_43__dId_11400839_.htm

---------------------------------------------

Published Date : 11.01.2010

 

Kursziel 4 $ "Emerging Markets Investor"

Für die Experten von "Emerging Markets Investor" ist die Lotus Pharmaceuticals-Aktie ein klarer Verdreifachungskandidat für 2010. Das Papier werde sofort in das neue Musterdepot aufgenommen. (Ausgabe 01 vom 11.01.2010) (12.01.2010/ac/a/a)

http://www.finanzen.net/analyse/...e-Emerging_Markets_Investor_350193

 ---------------------------------------------

Published Date : 30.11.2009

 

Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
BEIJING, Nov. 30 /PRNewswire


 End of 2010 with an estimated 25% in net margin..
http://www.prnewswire.com/news-releases/...-drug-stores-78125372.html
 

---------------------------------------------


Published Date : 21.12.2009

 

Lotus Pharmaceuticals kaufen "Hot Stocks Investor"


Endingen (aktiencheck.de AG) - Die Experten von "Hot Stocks Investor" raten die Lotus Pharmaceuticals-Aktie (ISIN US5457151042/ WKN A0MNCW) zu kaufen.


http://www.ariva.de/news/...ticals-kaufen-Hot-Stocks-Investor-3165485

---------------------------------------------

Published Date : 1 July 2009


Lotus Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances


http://www.aarkstore.com/reports/...-and-Alliances-Profile-20346.html

 

---------------------------------------------

 

"ACHTUNG KEINE KAUFEMPFEHLUNG"

 

27.01.10 18:42

5783 Postings, 3884 Tage Kleine_prinzKey stats and ratios ;-))

 
 Q3 (Sep 09)  2008
Net profit margin  37.15%  17.33%  
Operating margin  41.43%  20.42%  
EBITD margin  -  21.28%  
Return on average assets  28.23%  25.43%  
Return on average equity  37.99%  35.64%  
Employees  

199

 

28.01.10 17:27

5783 Postings, 3884 Tage Kleine_prinzWow Kein Wunder das sie..

So schnell wachsen bei der riesige Produkt Palette ;-)

Mein Persönlichen Kursziel Ende 2010 6 - 8 Euro ;-)

Die sind wie eine Medikamente Fabrik ;-))

 

Wow da wird sich hier noch viel tun bin mir ganz sicher ;-)

 

Lotus has a number of drugs waiting approval from the SFDA

http://www.lotuspharma.com/Development%20Portfolio.html

Drug NameTarget Area
Sodium aescinateCentral nervous system
Gatifloxacin lactateAnti-infectives
Calcium dibutyryl adenosine-monophosphateCardiovascular
GliclazideDiabetes
Salbutamol sulfateRespiratory
Rabeprazole sodiumGastrointestina
Compound allantoinGastrointestinal
NimesulideInflammatory
LovastatinCardiovascular
Compound metoprolo felodipineCardiovascular
CandesartanCardiovascular
Hawthorn flavonoidsCardiovascular
Compound balloonflower granulesRespiratory
Aster monomerInflammatory

 

Lotus Pharmaceuticals in Taiwan :-)))

http://www.lotuspharm.com.tw/english/internet/home/index.asp

 

01.02.10 19:58

5783 Postings, 3884 Tage Kleine_prinzLotus Pipeline new market report released

            2010-02-01 18:15:05 - Lotus Pharmaceuticals, Inc.-Detailed Product Pipeline - a new market research report on companiesandmarkets.com

                       

www.companiesandmarkets.com/Summary-Company-Profile/lotus-pharma ..

Lotus Pharmaceuticals, Inc.-Detailed Product Pipeline Pipeline Report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news on the company including key milestones.

Scope of the reports

Each Pipeline Report provides the user with real detail on a company"s pipeline.

In addition to business summaries, contact information, company details and selected financial data,

       
     

               

each report also contains extensive information in tabular and graphical formats on a company"s product pipeline and disease hub classification.

Product details consist of complete descriptions, therapeutic indication, drug class, mechanism of action and clinical trial
information. Every report also includes detail on a company"s deals and alliances and recent corporate news including key milestones.

Key benefits

    * Understand a company"s strategic position by accessing detailed independent intelligence on its product pipeline.
    * Keep track of your competitors and partners by better understanding their product pipeline.
* Monitor a company"s research effectiveness by determining pipeline depth and numbers of products in development by clinical phase.
               

               

 

http://www.pr-inside.com/lotus-pharmaceuticals-inc-detailed-product-r1698217.htm  

03.02.10 15:08

5783 Postings, 3884 Tage Kleine_prinzLotus Pharmaceuticals Chinas Flagship Product?

China’s Basic Medical Insurance to Cover Sinobiopharma’s Flagship Product

By Justin Kuepper · Tuesday, February 2nd, 2010

Sinobiopharma, Inc. (SNBP), which aims to become the next Teva Pharmaceuticals (TEVA) by competing in the Chinese pharmaceutical market alongside competitors like Lotus Pharmaceuticals (LTUS),announced government coverage of its flagship product.

Sinobiopharma, Inc. (“Sinobiopharma” or, the “Company”) (OTC Bulletin Board: SNBP) is pleased to announce that the Chinese government has approved the Company’s flagship product, KuTai (Cisatracurium Besylate), for coverage under National Basic Medical Insurance, Employment Injury Insurance and Maternity Insurance (2009 Edition).

KuTai (Cisatracurium Besylate), on the market since 2006, had not been covered by any medical insurance before the Chinese government granted approval for its inclusion on the list of insured drugs on November 27, 2009. Before coverage was approved, patients who chose KuTai, a lasted generation skeletal muscle relaxant used for surgery, did so at their own expense. National Basic Medical Insurance will now provide for patients to be reimbursed for any use of KuTai. Under China’s healthcare reform plan, more than 90 percent of its urban population of 600 million will be covered by National Basic Medical Insurance by the end of 2010.

Typically, the Chinese government observes the performance of new generation drugs in the market for several years to ensure their safety and efficacy profile is well established before considering them for inclusion on the list of insured pharmaceuticals. Following Sinobiopharma’s launch of this latest generation of muscle relaxant in China in 2006, KuTai has became one of the market growth leaders and is now used in more than 1,000 hospitals located in almost every province.

“We are very pleased that KuTai has finally been approved for insurance coverage,” said Dr. Lequn Lee Huang, Sinobiopharma CEO. “All of KuTai’s competitor drugs, earlier generation muscle relaxants, were covered by insurance. But even with this reimbursement disadvantage, KuTai still managed to gain significant market share because of its greater efficacy and superior safety profile. KuTai’s inclusion on the list of insured drugs eliminates this reimbursement disadvantage. We expect the provision of insurance coverage will drive a significant increase in KuTai’s sales volume and further gains in market share.”

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world’s fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include “forward-looking statements” regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.

 

http://theotcinvestor.com/...ver-sinobiopharmas-flagship-product-615/

 

03.02.10 15:13

5783 Postings, 3884 Tage Kleine_prinzI also recommended Lotus Pharmaceuticals..

Alles in DE ;-))))

http://de.babelfish.yahoo.com/...p=en_de&btnTrUrl=%C3%9Cbersetzen

 

I also recommended Lotus Pharmaceuticals (OTC BB: LTUS) on January 25 when it was trading with a trailing PE of just 4. I wrote, "Just sit tight while this stock fluctuates and in another six months you'll be very glad you did. It's not unreasonable to think that shares could double in the next year."

And fluctuate shares have, falling to $1.40 and providing a nice entry point (or a place to add to an existing position). At this level the stock is trading with a PE of just 3.4, dirt cheap even for a highly speculative over-the-counter traded pharmaceutical stock like Lotus. Look for shares to move higher in the near-term and much higher in the long-term.

The China bears are missing the key points on why China represents such a compelling investment right now. Domestic consumption is growing in China leading consumer spending to rise 16.9% in 2009. Not to mention, China's government is proactively dealing with monetary policy before inflation becomes an issue (U.S., eat your heart out). Finally, China is extremely friendly to foreign investors, despite its Communist government. And Beijing rewards investors that invest capital by having no capital gains tax, no estate tax, and no property tax.   

The recent sell-off has left Chinese stocks trading at dirt cheap valuations, despite their strong growth prospects. Right now is the time to take positions in quality Chinese stocks at attractive valuations. 

If you would like to learn more about the companies I recommend, I encourage you to begin a trial subscription to Small Cap Investor PRO. You can likely cover the cost of a yearly subscription within just a few weeks of investing in my favorite stocks. Plus there is absolutely no risk when you sign up for a trial subscription. Just click here to find out more about how you can get started with Small Cap Investor PRO today.

 

http://www.smallcapinvestor.com/smallcapnews/...ears_should_hibernate

 

03.02.10 15:18

5783 Postings, 3884 Tage Kleine_prinzInlandsverbrauch wächst in China ;-)

warum China solch eine unwiderstehliche Investition im Augenblick darstellt. Inlandsverbrauch wächst in China-führenden Verbraucherausgaben, um zu steigen 16.9% 2009. Ganz zu schweigen von, Chinas beschäftigt Regierung proaktiv Geld- und Kreditpolitik, bevor Inflation eine Ausgabe wird (US, essen Ihr Herz heraus). Schließlich ist China zu den fremden Investoren, trotz seiner kommunistischen Regierung extrem freundlich. Und Peking-Belohnungsinvestoren, die investieren Kapital indem sie keine Kapitalgewinnsteuer, keine Nachlasssteuer und keine Vermögenssteuer haben.     

Seite:
| 2 | 3  
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Aramco (Saudi-Aramco)A2PVHD
Daimler AG710000
Deutsche Bank AG514000
EVOTEC SE566480
NEL ASAA0B733
K+S AGKSAG88
Microsoft Corp.870747
Apple Inc.865985
BVB (Borussia Dortmund)549309
Varta AGA0TGJ5
BASFBASF11
Amazon906866
Ballard Power Inc.A0RENB
Deutsche Telekom AG555750